Antibody responses to borrelia IR6 peptide variants and the C6 peptide in Swedish patients with erythema migrans
The aim of this study was to evaluate the antibody responses to different VIsE protein IR6 peptide variants and the synthetic C6 peptide in acute and convalescent (2-3 and 6 months) serum samples from Swedish patients with clinical erythema migrans (EM). Serum samples were prospectively collected from 148 patients with EM and compared to serum samples obtained from 200 healthy blood donors. The Ig